AACR 2022 | MatchMiner: A new method of matching patients to precision medicine trials

Harry Klein, PhD, Dana Farber Cancer Institute, Boston, MA, talks on the MatchMiner platform from Dana-Farber Cancer Institute, which is an open-source platform that aims to match patients to precision medicine clinical trials. Tumor sequencing data from patients is used to match them to trials via eligibility criteria. 220 patients have been matched to trials so far and, on average, patients who are matched with a precision medicine trial through MatchMiner get to trial 55 days sooner than those who did not get matched by the platform. Dr Klein also discusses the next steps for MatchMiner and requests that other institutions interested in the platform get in touch to collaborate. This interview took place at the American Association for Cancer Research Annual Meeting in New Orleans, LA.